广东医学2026，Vol.47Issue(3)：321-325,5.DOI:10.13820/j.cnki.gdyx.20254240
麻醉药物治疗神经精神疾病的机遇与挑战
Opportunities and challenges of anesthetic agents in the treatment of neuropsychiatric disorders
摘要
Abstract
With the deepening of research,the therapeutic potential of traditional anesthetic agents in neuropsy-chiatric disorders has attracted increasing attention.Representative agents such as ketamine,sevoflurane,and xenon have been shown to rapidly alleviate symptoms of conditions including depression and autism spectrum disorders when adminis-tered at subanesthetic doses,and some have already entered clinical trial stages.However,the clinical application of an-esthetic drugs as psychiatric treatments still faces several important challenges.First,the safety window and long-term toxicity remain unclear,particularly in adolescents and patients requiring prolonged treatment.Second,some anesthetic a-gents possess abuse liability and addictive potential,necessitating strict regulatory frameworks for clinical use.Third,in-terindividual variability in treatment response and the uncertainty associated with subjective rating scales limit precise eval-uation of therapeutic efficacy.Mechanistic studies suggest that anesthetic agents may exert neuromodulatory effects by reg-ulating the balance between excitatory and inhibitory neurotransmission and enhancing synaptic plasticity,highlighting their potential application in neurodevelopmental disorders.To facilitate safe and standardized clinical translation,closer interdisciplinary collaboration between psychiatry and anesthesiology is required.In addition,further efforts are needed to develop reliable biomarkers,clarify underlying mechanisms,and establish multidisciplinary collaborative frameworks at the levels of policy,education,and research.关键词
麻醉药物/神经精神类疾病/治疗Key words
anesthetic agents/neuropsychiatric disorders/treatment分类
医药卫生引用本文复制引用
郭欣莹,宋兴荣..麻醉药物治疗神经精神疾病的机遇与挑战[J].广东医学,2026,47(3):321-325,5.基金项目
国家自然科学基金资助项目(82471292,82401457) （82471292,82401457）
广州医科大学科研能力提升计划重大临床研究项目(GMUCR2025-01011) （GMUCR2025-01011）
